Palantir PLTR.US closed down 6.20% on Wednesday with a trading volume of $9.33 billion; Michael Burry publicly criticized, intensified competition from Anthropic leads to sell-off

Stock Performance

According to Gold Pattern Express APP, during US stock trading on Wednesday (April 8), $Palantir (PLTR.US)$ ranked 11th in turnover, reaching $9.33 billion, and closed down 6.20%.

Against the backdrop of a broad-based rebound in US stocks, Palantir’s notable decline bucked the trend. The high trading volume combined with a significant drop indicates concentrated selling pressure being released. In the short term, panic sentiment and the exit of momentum traders became the main driving force, resulting in a rapid pullback in the share price.

Criticism from Michael Burry

Famed investor Michael Burry publicly criticized Palantir, noting that its market share is being eroded by competitors. This statement quickly spread in the market, triggering a panic sell-off by retail and momentum traders.

Burry’s criticism focused on the sustainability of Palantir’s business model and the worsening competitive landscape. Combined with valuation pressures, this further amplified the market’s doubts regarding the company’s growth narrative.

Competitive Pressure from Anthropic

Burry specifically pointed out that emerging AI companies such as Anthropic are rapidly encroaching on Palantir’s traditional areas of strength. With the progress made by Anthropic and its Claude series models in enterprise AI applications, Palantir’s data analytics and decision platforms face direct competition.

The market is concerned that Palantir’s leading position in the AI-driven big data analytics market is under threat, especially as competitors demonstrate advantages in model capabilities, deployment speed, and cost efficiency. Palantir’s growth trajectory may be squeezed as a result.

Valuation and Ethical Review

Palantir’s current trading price carries a significant premium, and the market generally believes its valuation fully or even excessively reflects expectations of high future growth. If execution wavers in any way, the premium will quickly contract.

In addition, ethical reviews and opposition voices from the UK National Health Service (NHS) and defense sectors regarding collaboration with Palantir continue to persist, further increasing regulatory and reputational risk. This noise has heightened investor caution, becoming an ancillary factor in the stock’s decline.

Benchmark Coverage Report

Benchmark initiated coverage on Palantir for the first time, giving a "Hold" rating but setting a target price of only $150, which is significantly below market consensus. The institution reiterated its bearish view, stating that Palantir must maintain a very high growth rate to justify its current premium.

Analysts warn that any misstep in execution could lead to significant downside risk for the growth narrative. Benchmark’s conservative price target has further intensified concerns over the rationality of Palantir’s valuation.

Investment Insights

On Wednesday, Palantir fell 6.20% against the market, primarily due to Michael Burry’s public criticism, intensified competition from Anthropic, and a combination of valuation and regulatory noise. The rapid retreat on high volume indicates that investors should be wary of short-term, emotion-driven volatility.

In the long run, Palantir’s technological accumulation in big data analytics and AI decision platforms still holds potential, but the deteriorating competitive landscape and high valuation pressure mean the company must consistently deliver high growth. Investors should closely monitor the actual landing of contracts, revenue quality, and competitor dynamics.

Editor’s Summary

On Wednesday, Palantir (PLTR.US) ranked 11th in US stock turnover but closed down 6.20%. Michael Burry’s public criticism combined with market erosion by competitors such as Anthropic was the main driver behind the share price correction. UK ethical reviews and the high valuation premium further amplified investor caution, and Benchmark’s $150 target price, which is well below consensus, intensified bearish voices. Despite Palantir’s continuing technological advantages in the data platform sector, its high-growth narrative is facing increasingly stringent scrutiny. While following the long-term AI trend, investors should rationally assess execution risk and valuation safety margin to avoid losses caused by emotional trading.

Frequently Asked Questions

Q: Why did Michael Burry publicly criticize Palantir?
A: Burry pointed out that Palantir’s market share is being rapidly eroded by competitors such as Anthropic, and believes the company’s business model sustainability is being challenged. This criticism directly triggered panic among retail and momentum traders, resulting in short-term concentrated selling pressure.

Q: What kind of competitive threat does Anthropic pose to Palantir?
A: Leveraging the Claude AI model series, Anthropic has made rapid progress in enterprise-level data analytics and decision-making applications, eating into Palantir’s traditional strengths. Competitors’ improvements in model capability, deployment flexibility, and cost efficiency put additional pressure on Palantir’s growth narrative.

Q: What is the specific impact of the UK ethical review on Palantir?
A: Opposition to Palantir collaborations continues from the UK National Health Service (NHS) and the defense sector, raising regulatory and reputational risks. This noise has intensified investor caution, acting as an additional catalyst for the share price drop and further amplifying valuation concerns.

Q: What is Benchmark’s coverage perspective on Palantir?
A: Benchmark initiated coverage with a “Hold” rating but set a target price of only $150, significantly below the market consensus. The institution believes Palantir must maintain very high growth to justify its current premium and warns that any execution misstep could substantially widen the downside risk.

Q: How should ordinary investors view Palantir’s investment opportunity now?
A: In the short term, be alert to the selling pressure and valuation pullback risk triggered by Burry’s criticism; the 6.20% drop on high trading volume signals emotion-driven moves. In the long term, Palantir’s technological accumulation in big data and AI decision platforms still holds promise, but focus should be on tracking actual contract execution, revenue quality, and competition with Anthropic and other rivals. It is advisable to wait for a more reasonable valuation range and strictly control position size, avoiding volatility brought by a singular reliance on the high-growth narrative.